ORCA Therapeutics licenses oncolytic adenovirus technology from VCN Biosciences
ORCA Therapeutics BV announced that it has obtained an exclusive license from VCN Biosciences SL of Gelida (Barcelona), Spain, to their T1 oncolytic adenovirus technology for the treatment of cancer. This license allows ORCA Therapeutics to develop and commercialize new, next generation oncolytic adenoviruses with increased oncolytic potency.
“We are very excited to have in-licensed this technology from VCN Biosciences. Securing this intellectual property will enhance our competitive position in virotherapy” said Dr Janneke Meulenberg, CEO of ORCA Therapeutics “We now have the unique opportunity to combine our oncolytic adenovirus technology and know-how with VCN Biosciences’ state of the art T1 technology to develop more effective oncolytic adenoviruses for treatment of cancer.”
Oncolytic adenoviruses are engineered to replicate selectively in cancer cells. They kill these cells by their inherent capacity to lyse their host cell. Upon destroying infected cancer cells, progeny viruses are released that in turn will infect and kill adjacent cancer cells. This results in a strong anti-cancer effect. The T1 technology provides a novel mechanism to increase the release of adenovirus from infected tumor cells. A team led by Dr Ramon Alemany and Dr Manel Cascallo from the Catalan Institute of Oncology identified a unique mutation in the endoplasmic reticulum retention domain of the adenovirus E3/19K protein (445A mutation). This mutation causes enhanced oncolytic potency in human tumors and cancer-associated fibroblasts in vitro and enhanced anti-tumor activity when injected intra-tumorally or systemically in different cancer models in vivo.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Bentley Pharmaceuticals and the University of New Hampshire Announce Advances in Nanotechnology Research Program

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"
Walter Reed Army Institute and Siam Life Science Develop New Gold Standard for Pharmacological and Toxicological Test Systems - Siam Life Science Secures Exclusive License For Unique Liver Cell Line From Walter Reed Army Institute Of Research
Artificial 'plants' could fuel the future
Novasep Appoints a New Chairman for its Supervisory Board - Bernard Dubois, Former Aventis Senior VP of Global Industrial Operations Brings a Wealth of Experience to Novasep's Top Management Team
